Physician profile
Nichole Stanley
NPI 1154976595
$18,499.60
in general payments reported to CMS, 2019-2025
36 companies · $7,359 in 2025
The $7,359 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,313 · 2022: $2,142 · 2023: $2,300 · 2024: $4,386 · 2025: $7,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $2,263 · Consulting Fee: $1,260 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,442.57 |
| Travel and Lodging | $2,262.95 |
| Consulting Fee | $1,260.00 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,688.53 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $2,342.95 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $2,205.34 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,598.58 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $999.08 | 2022-2025 | Glassia |
| United Therapeutics Corporation | $871.93 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Regeneron Healthcare Solutions, INC. | $803.60 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.87 | 2021-2025 | Ofev, Stiolto Respimat, Jascayd |
| Jazz Pharmaceuticals INC. | $699.65 | 2021-2025 | |
| Baxter Healthcare | $624.50 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Actelion Pharmaceuticals US, INC. | $456.44 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $389.15 | 2021-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $379.97 | 2021-2024 | Yupelri |
| Axsome Therapeutics, INC. | $376.82 | 2022-2024 | Sunosi |
| Grifols USA, LLC | $320.66 | 2021-2025 | Prolastin-C Liquid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $236.15 | 2022-2025 | Winrevair, Belsomra |
| Amgen INC. | $229.31 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $186.30 | 2025 | Yupelri |
| Verona Pharma, INC. | $142.17 | 2025 | Ohtuvayre |
| Electromed, INC. | $140.78 | 2023-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $138.89 | 2021 | |
| Pulmonx Corporation | $125.31 | 2021 | |
| Philips North America LLC | $105.22 | 2021-2025 | Vest Therapy Und |
| Eisai INC. | $103.95 | 2021 | |
| Advanced Respiratory, INC | $87.37 | 2021 | |
| Astellas Pharma US INC | $84.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $80.69 | 2021-2024 | Xarelto |
| Inogen, INC. | $76.99 | 2022-2025 | Inogen |
| Bayer Healthcare Pharmaceuticals INC. | $46.59 | 2023-2025 | |
| Harmony Biosciences LLC | $42.54 | 2023 | Wakix |
| Teva Pharmaceuticals USA, INC. | $33.35 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $32.66 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $32.32 | 2021 | |
| Paratek Pharmaceuticals, INC. | $30.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.22 | 2021-2023 | Eliquis |
| Lilly USA, LLC | $14.02 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Stanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.